Moderna, Inc. (MRNA) experienced a significant price surge during Monday's intraday trading session, with shares soaring 5.05%.

The sharp increase follows positive analyst action, as Piper Sandler raised its price target on Moderna to $69 from $63 while maintaining an Overweight rating on the stock. This upward revision reflects growing analyst confidence in the company's prospects and typically signals to investors that the stock may be undervalued relative to its potential.